Aliases & Classifications for Myofascial Pain Syndrome

MalaCards integrated aliases for Myofascial Pain Syndrome:

Name: Myofascial Pain Syndrome 12 15 17
Myofascial Pain Syndromes 44 71
Myofascial Pain Dysfunction Syndrome 54
Fibromyalgia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:431
MeSH 44 D009209
UMLS 71 C0016053 C0027073

Summaries for Myofascial Pain Syndrome

MalaCards based summary : Myofascial Pain Syndrome, also known as myofascial pain syndromes, is related to fibromyalgia and glossopharyngeal neuralgia, and has symptoms including muscle weakness, fatigue and myoclonus. An important gene associated with Myofascial Pain Syndrome is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Gabapentin and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, spinal cord and cortex, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized... more...

Related Diseases for Myofascial Pain Syndrome

Diseases related to Myofascial Pain Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 fibromyalgia 31.6 POMC NGF CALCA BDNF
2 glossopharyngeal neuralgia 30.8 TAC1 POMC
3 bruxism 30.6 TAC1 LAPTM4A
4 radiculopathy 30.3 TAC1 LAPTM4A
5 hypochondriasis 30.2 POMC BDNF
6 frozen shoulder 30.2 LAPTM4A ASIC3
7 pulpitis 30.1 TRPV1 KNG1
8 facial neuralgia 30.1 TAC1 LIPN LAPTM4A
9 complex regional pain syndrome 30.1 TAC1 POMC CALCA
10 sleep disorder 29.9 TAC1 POMC BDNF
11 bursitis 29.8 TAC1 LAPTM4A KNG1 CALCA
12 anxiety 29.5 TAC1 POMC NGF BDNF
13 reflex sympathetic dystrophy 29.4 TRPV1 TAC1 LAPTM4A KNG1 CALCA
14 algoneurodystrophy 29.4 TAC1 NGF KNG1 CALCA
15 major depressive disorder 29.3 TAC1 POMC NGF BDNF
16 irritable bowel syndrome 29.2 TRPV1 TAC1 POMC NGF BDNF
17 somatoform disorder 29.0 TRPV1 TAC1 NGF LAPTM4A CALCA BDNF
18 paine syndrome 28.8 TRPV1 TAC1 NGF LAPTM4A KNG1 CALCA
19 trigeminal neuralgia 28.4 TRPV1 TAC1 NGF LIPN KNG1 CALCA
20 peripheral nervous system disease 28.3 TRPV1 TAC1 POMC NGF KNG1 CALCA
21 chronic pain 10.6
22 trichorhinophalangeal syndrome 10.5
23 chronic fatigue syndrome 10.4
24 patellofemoral pain syndrome 10.3 TAC1 LAPTM4A
25 neurodermatitis 10.3 TAC1 POMC
26 arachnoiditis 10.3 TAC1 POMC
27 somatization disorder 10.3 TAC1 POMC
28 shoulder impingement syndrome 10.3 TAC1 LAPTM4A
29 ectopic cushing syndrome 10.3 POMC CALCA
30 carbamazepine allergy 10.3 TAC1 CALCA
31 taylor's syndrome 10.3 TAC1 CALCA
32 nasal cavity adenocarcinoma 10.2 POMC CALCA
33 motion sickness 10.2 TAC1 POMC
34 graves disease 1 10.2 POMC CALCA
35 interval angle-closure glaucoma 10.2 TAC1 KNG1
36 intracranial vasospasm 10.2 TAC1 KNG1
37 acute apical periodontitis 10.2 TAC1 KNG1
38 sick building syndrome 10.2 TRPV1 POMC
39 akinetopsia 10.2 TAC1 KNG1
40 autonomic dysfunction 10.2
41 headache 10.2
42 spasticity 10.2
43 hyperhidrosis, gustatory 10.2 TRPV1 TAC1
44 premenstrual tension 10.2 POMC LIPN
45 facial dermatosis 10.2 TRPV1 TAC1
46 pseudopterygium 10.2 TRPV1 TAC1
47 lung oat cell carcinoma 10.2 POMC CALCA
48 atypical depressive disorder 10.2 POMC BDNF
49 retrograde amnesia 10.2 POMC BDNF
50 dental pulp disease 10.2 TRPV1 TAC1

Graphical network of the top 20 diseases related to Myofascial Pain Syndrome:



Diseases related to Myofascial Pain Syndrome

Symptoms & Phenotypes for Myofascial Pain Syndrome

UMLS symptoms related to Myofascial Pain Syndrome:


muscle weakness, fatigue, myoclonus, back pain, myalgia, torticollis, pain, chronic pain, sciatica, muscle cramp, muscle rigidity, muscle spasticity, myofascial trigger point pain

GenomeRNAi Phenotypes related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.36 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.36 NGF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.36 NGF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.36 NGF
5 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.36 NGF
6 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.36 LAPTM4A POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.36 NGF
8 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.36 LAPTM4A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.36 LAPTM4A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.36 POMC

MGI Mouse Phenotypes related to Myofascial Pain Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 ASIC3 BDNF KNG1 NGF PDGFRB POMC
2 homeostasis/metabolism MP:0005376 9.61 ASIC3 BDNF KNG1 LAPTM4A LIPN NGF
3 integument MP:0010771 9.17 ASIC3 BDNF NGF PDGFRB POMC TAC1

Drugs & Therapeutics for Myofascial Pain Syndrome

Drugs for Myofascial Pain Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Perphenazine Approved Phase 4 58-39-9 4748
5
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
6
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
10
tannic acid Approved Phase 4 1401-55-4
11
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
16
Flunarizine Approved Phase 4 52468-60-7 941361
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Amitriptyline Approved Phase 4 50-48-6 2160
19
Citalopram Approved Phase 4 59729-33-8 2771
20
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
23
Ethanol Approved Phase 4 64-17-5 702
24
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
25
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
26
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
27
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
28
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
29
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
30
Suvorexant Approved, Investigational Phase 4 1030377-33-3
31
Promethazine Approved, Investigational Phase 4 60-87-7 4927
32
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
33
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
36 Cyclooxygenase 2 Inhibitors Phase 4
37 Gastrointestinal Agents Phase 4
38 Antipsychotic Agents Phase 4
39 Antiemetics Phase 4
40 Quetiapine Fumarate Phase 4 111974-72-2
41 Central Nervous System Stimulants Phase 4
42 Citrate Phase 4
43 Anesthetics, Intravenous Phase 4
44 Anesthetics, General Phase 4
45 Cytochrome P-450 Enzyme Inhibitors Phase 4
46 Histamine Antagonists Phase 4
47
Histamine Phosphate Phase 4 51-74-1 65513
48 Histamine H1 Antagonists Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 824)
# Name Status NCT ID Phase Drugs
1 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
2 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
3 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study. Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
4 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
5 A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study Completed NCT00600574 Phase 4
6 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
7 Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi Completed NCT00550641 Phase 4
8 Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia Completed NCT01226667 Phase 4 Pregabalin
9 A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia Completed NCT00766350 Phase 4 amitriptyline;quetiapine
10 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
11 Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II) Completed NCT00791739 Phase 4 trazodone, pregabalin
12 The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study Completed NCT00272532 Phase 4 Thiocolchicoside
13 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
14 An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran Completed NCT01125423 Phase 4 Milnacipran
15 A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran Completed NCT01038323 Phase 4 Educational with milnacipran
16 A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia Completed NCT01020526 Phase 4 pregabalin
17 A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia Completed NCT01020474 Phase 4 placebo;pregabalin (Lyrica)
18 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine
19 Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study Completed NCT01288807 Phase 4 Milnacipram
20 Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain Completed NCT02078791 Phase 4 Botox infiltration
21 A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia Completed NCT01173055 Phase 4 milnacipran;Placebo
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Completed NCT01077375 Phase 4 Placebo;Milnacipran
23 A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment Completed NCT01014585 Phase 4 Placebo;Milnacipran
24 Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial. Completed NCT00610610 Phase 4 Paroxetine CR;Placebo
25 Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia Completed NCT00392041 Phase 4 Eszopiclone;placebo
26 Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia Completed NCT00766675 Phase 4 Tramadol hydrochloride;Acetaminophen
27 Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial Completed NCT02063750 Phase 4
28 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia Completed NCT01234675 Phase 4 Milnacipran;Placebo
29 Combining N-of-1 Trials to Assess Fibromyalgia Therapies Completed NCT00000428 Phase 4 Amitriptyline;Amitriptyline plus Fluoxitine
30 Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia Completed NCT00673452 Phase 4 duloxetine hydrochloride;placebo
31 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome. Completed NCT00675896 Phase 4 Quetiapine Fumarate Sustained Release;Placebo
32 A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia Completed NCT00965601 Phase 4
33 Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study Completed NCT00983320 Phase 4 quetiapine;placebo
34 A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia Completed NCT00965081 Phase 4 Duloxetine;Placebo
35 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
36 Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study Completed NCT04123652 Phase 4 Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
37 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
38 The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles Completed NCT02230371 Phase 4 Granisetron;Control (placebo)
39 Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial Completed NCT04040309 Phase 4 Lidocaine injection
40 Neurologic Signatures of Chronic Pain Disorders Completed NCT02747940 Phase 4 flunarizine and/or pregabalin
41 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
42 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
43 Efficacy and Tolerability of Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients: A Double-blind, Randomized, Placebo-controlled Clinical Trial Recruiting NCT04488926 Phase 4 Standard Therapy;Rescue Drug
44 Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) Recruiting NCT04245748 Phase 4 Escitalopram;Duloxetine
45 Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia Recruiting NCT04158752 Phase 4 Galcanezumab
46 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Active, not recruiting NCT03271151 Phase 4 Cymbalta
47 Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points in Masseter Muscle Not yet recruiting NCT04742140 Phase 4 Magnesium sulfate;Saline
48 Effectiveness, Cost-utility and Neurobiological Effects of Low-dose Naltrexone in Patients With Fibromyalgia (INNOVA Project) Not yet recruiting NCT04739995 Phase 4 Low-dose naltrexone
49 Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial. Terminated NCT00628355 Phase 4 lidocaine
50 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone

Search NIH Clinical Center for Myofascial Pain Syndrome

Cochrane evidence based reviews: myofascial pain syndromes

Genetic Tests for Myofascial Pain Syndrome

Anatomical Context for Myofascial Pain Syndrome

MalaCards organs/tissues related to Myofascial Pain Syndrome:

40
Skeletal Muscle, Spinal Cord, Cortex, Amygdala, Pineal, Skin, Brain

Publications for Myofascial Pain Syndrome

Articles related to Myofascial Pain Syndrome:

(show top 50) (show all 821)
# Title Authors PMID Year
1
An unusual complication of quadriparesis after trigger point injection: a case report. 61
33009247 2021
2
Specialty-Specific Diagnoses in Pediatric Patients With Postconcussion Syndrome: Experience From a Multidisciplinary Concussion Clinic. 61
33605602 2021
3
The association between exposure to domestic abuse in women and the development of syndromes indicating central nervous system sensitisation: a retrospective cohort study using UK primary care records. 61
33559289 2021
4
The Effect of Extracorporeal Shock Wave Therapy on Pain Intensity and Neck Disability for Patients With Myofascial Pain Syndrome in the Neck and Shoulder: A Meta-Analysis of Randomized Controlled Trials. 61
32520797 2021
5
"Quantitative Ultrasound Texture Feature Changes with Conservative treatment of the Trapezius Muscle in female patients with Myofascial Pain Syndrome". 61
33480607 2021
6
Optimal duration of stretching exercise in patients with chronic myofascial pain syndrome: A randomized controlled trial. 61
33367925 2021
7
Effectiveness of extracorporeal shock wave therapy versus standard care in the treatment of neck and upper back myofascial pain: a single blinded randomised clinical trial. 61
32731757 2021
8
Predictive factors of response in radial Extracorporeal Shock-waves Therapy for Myofascial and Articular Pain: A retrospective cohort study. 61
33492278 2021
9
Leiomyosarcoma of the small intestine presenting as abdominal myofascial pain syndrome (AMPS): case report. 61
32970610 2021
10
Comparative Effectiveness of Thai Herbal Formula (Thor-Ra-Nee-San-Tha-Kat) Versus Naproxen for Chronic Myofascial Pain: A Pilot Randomized-Controlled Trial. 61
33216613 2021
11
Ultrasound-guided interventional procedures for myofascial trigger points: a systematic review. 61
33159004 2021
12
Effects of cognitive behavioral therapy on orofacial pain conditions. 61
33298629 2020
13
The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. 61
33383293 2020
14
Quantitative response of healthy muscle following the induction of capsaicin: an exploratory randomized controlled trial. 61
33308274 2020
15
Neuroticism Traits and Anxiety Symptoms are Exhibited in Athletes With Chronic Gastrocnemius Myofascial Pain Syndrome. 61
33065704 2020
16
Sonography-guided trigger point injections in abdominal myofascial pain syndrome. 61
33285730 2020
17
Characteristics of chiropractic patients treated at the University of Johannesburg chiropractic student clinic and relevance to the educational process. 61
33316062 2020
18
Criteria Used for the Diagnosis of Myofascial Trigger Points in Clinical Trials on Physical Therapy: Updated Systematic Review. 61
32841969 2020
19
Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection. 61
33374687 2020
20
Effect of Physical Exercise Programs on Myofascial Trigger Points-Related Dysfunctions: A Systematic Review and Meta-analysis. 61
33011790 2020
21
Needling on trigger point promotes muscle regeneration after bupivacaine injection induced injury. 61
33132179 2020
22
The efficacy of fascial plane blocks for myofascial pain syndrome: do they achieve long-term results? 61
33271010 2020
23
The pathophysiological nature of sarcomeres in trigger points in patients with myofascial pain syndrome: A preliminary study. 61
32841448 2020
24
Serum inflammatory and oxidative stress biomarkers levels are associated with pain intensity, pressure pain threshold and quality of life in myofascial pain syndrome. 61
33160410 2020
25
Moxibustion therapy on myofascial pain syndrome: An evidence-based clinical practice guideline. 61
33181637 2020
26
Myofascial Pain Syndrome and Its Relation to Trigger Points, Facial Form, Muscular Hypertrophy, Deflection, Joint Loading, Body Mass Index, Age and Educational Status. 61
33437714 2020
27
Prevalence And Impact Of Myofascial Pain Syndrome In Relapsing-Remitting Multiple Sclerosis And The Effects Of Local Anesthetic Injections For Short-Term Treatment. 61
33022587 2020
28
Comments on Aydin et al: The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; a Prospective Randomized Clinical Study. 61
32358602 2020
29
Authors' Reply: Letter to the Editor Regarding "The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; Prospective Randomized Clinical Study". 61
32358610 2020
30
Transcranial direct current stimulation improves myofascial pain syndrome and chronic fatigue. 61
33213134 2020
31
An electroencephalography (EEG) study of short-term electromyography (EMG) biofeedback training in patients with myofascial pain syndrome in the upper trapezius. 61
33132529 2020
32
The assessment of affective temperament and life quality in myofascial pain syndrome patients. 61
33084454 2020
33
Erector spinae plane block and rhomboid intercostal block for the treatment of post-mastectomy pain syndrome. 61
33447197 2020
34
Comparison of efficacy of corticosteroid injection versus extracorporeal shock wave therapy on inferior trigger points in the quadratus lumborum muscle: a randomized clinical trial. 61
33076888 2020
35
The Levels of Insulin-Like Growth Factor in Patients with Myofascial Pain Syndrome and in Healthy Controls. 61
33026183 2020
36
A systematic review of musculoskeletal complaints, symptoms, and pathologies related to mobile phone usage. 61
32861360 2020
37
Extra-spinal sciatica and sciatica mimics: a scoping review. 61
32989195 2020
38
Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter. 61
32753287 2020
39
The Influence of Pro-inflammatory Cytokines and Genetic Variants in the Development of Fibromyalgia: A Traditional Review. 61
33042712 2020
40
Ashi Acupuncture Versus Local Anesthetic Trigger Point Injections in the Treatment of Abdominal Myofascial Pain Syndrome: A Randomized Clinical Trial. 61
32967393 2020
41
Ultrasound-guided dextrose injection treatment for chronic myofascial pain syndrome: A retrospective case series. 61
32349034 2020
42
Rate and maintenance of improvement of myofascial pain with dry needling alone vs. dry needling with intramuscular electrical stimulation: a randomized controlled trial. 61
32990529 2020
43
A comparison of dry needling and kinesiotaping therapies in myofascial pain syndrome: A randomized clinical study. 61
33089092 2020
44
Opioid Reduction and Long-Term Outcomes in Abdominal Myofascial Pain Syndrome (AMPS): A 6-Year Longitudinal Prospective Audit of 207 Patients. 61
32967395 2020
45
Myofascial Pain Syndrome: A Narrative Review Identifying Inconsistencies in Nomenclature. 61
31736284 2020
46
Ultrasound measurements of superficial and deep masticatory muscles in various postures: reliability and influencers. 61
32873849 2020
47
Treatment and management of myofascial pain syndrome. 61
33004157 2020
48
Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome-An Evidence-Based Narrative Review and Etiological Hypothesis. 61
32992770 2020
49
Comparison of dry needling and trigger point manual therapy in patients with neck and upper back myofascial pain syndrome: a systematic review and meta-analysis. 61
32962567 2020
50
Clinical Characteristics of Myofascial Pain Syndrome with Psychological Stress in Patients with Cancer. 61
32996846 2020

Variations for Myofascial Pain Syndrome

Expression for Myofascial Pain Syndrome

Search GEO for disease gene expression data for Myofascial Pain Syndrome.

Pathways for Myofascial Pain Syndrome

Pathways related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.51 TRPV1 NGF KNG1 ASIC3
2 11.34 TAC1 NGF BDNF
3 10.66 TRPV1 NGF

GO Terms for Myofascial Pain Syndrome

Cellular components related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 TAC1 POMC NGF KNG1 CALCA BDNF
2 intrinsic component of plasma membrane GO:0031226 9.26 TRPV1 PDGFRB
3 axon GO:0030424 9.26 TAC1 NGF CALCA BDNF
4 extracellular region GO:0005576 9.17 TAC1 POMC NGF LIPN KNG1 CALCA

Biological processes related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.98 TAC1 POMC PDGFRB KNG1 CALCA
2 inflammatory response GO:0006954 9.83 TRPV1 TAC1 KNG1 CALCA
3 positive regulation of apoptotic process GO:0043065 9.81 TRPV1 PDGFRB NGF KNG1
4 cell-cell signaling GO:0007267 9.77 TAC1 POMC CALCA
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 PDGFRB NGF BDNF
6 neuropeptide signaling pathway GO:0007218 9.63 TAC1 POMC CALCA
7 regulation of neuron differentiation GO:0045664 9.59 NGF BDNF
8 peripheral nervous system development GO:0007422 9.58 NGF BDNF
9 regulation of blood pressure GO:0008217 9.58 TAC1 POMC CALCA
10 vasodilation GO:0042311 9.57 KNG1 CALCA
11 neurotrophin TRK receptor signaling pathway GO:0048011 9.56 NGF BDNF
12 nerve development GO:0021675 9.54 NGF BDNF
13 response to heat GO:0009408 9.54 TRPV1 CALCA ASIC3
14 nerve growth factor signaling pathway GO:0038180 9.49 NGF BDNF
15 negative regulation of heart rate GO:0010459 9.48 TRPV1 TAC1
16 positive regulation of cytosolic calcium ion concentration GO:0007204 9.46 TRPV1 TAC1 KNG1 CALCA
17 positive regulation of collateral sprouting GO:0048672 9.43 NGF BDNF
18 cellular response to nerve growth factor stimulus GO:1990090 9.43 TRPV1 TAC1 CALCA
19 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.32 TRPV1 ASIC3
20 response to pain GO:0048265 9.13 TRPV1 TAC1 CALCA
21 detection of temperature stimulus involved in sensory perception of pain GO:0050965 8.8 TRPV1 CALCA ASIC3

Molecular functions related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.1 POMC PDGFRB NGF KNG1 CALCA BDNF
2 nerve growth factor receptor binding GO:0005163 8.96 NGF BDNF

Sources for Myofascial Pain Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....